All In Biotech

NDA 050065 · Sandoz

Maxitrol

Dexamethasone, Neomycin Sulfate, Polymyxin B Sulfate · Ophthalmic · Corticosteroid

Last checked: Nov 20, 2026Latest source record: May 14, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1963

Jul 19, 1963

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4,222

936 Phase 3, 495 recruiting

FAERS reports

1,087

663 serious, 50 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 30, 2024.

INDICATIONS AND USAGE For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. This product does not provide adequate coverage against: Serratia marcescens and Streptococci , including Streptococcus pneumoniae.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 19, 1963 Original approval
1 products under this application
  • MAXITROL · DEXAMETHASONE 0.1%; NEOMYCIN SULFATE EQ 3.5MG BASE/GM; POLYMYXIN B SULFATE 10,000 UNITS/GM · OINTMENT, OPHTHALMIC · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Dexamethasone" as an intervention, any sponsor and status, largest first.

All 4,222 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain92
  • eye irritation80
  • vision blurred70
  • ocular hyperaemia60
  • off label use58
  • pain52
  • visual impairment52
  • drug ineffective48
  • headache46
  • fatigue42
  • dyspnoea39
  • condition aggravated37

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
20052
20066
200714
20087
200912
201021
20115
201221
201330
201433
201544
2016104
201756
201889
201994
2020106
202158
202277
202395
202477
202577
202653

Recalls

1 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Maxitrol (Neomycin/Polymyxin B/Dexametha)

2024 spending

$24K

Beneficiaries

129

143 claims

Per beneficiary

$185

$43.17 per unit

View as table
YearSpending
2020$0
2021$16,873
2022$19,810
2023$19,572
2024$23,892

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,424 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.